How to Understand the Exploding Evidence on New Circuit-Based TMS Targets

You're invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: How to Understand the Exploding Evidence on New Circuit-Based TMS Targets, featuring Shan Siddiqi, MD! 

We are currently in the midst of a rapid growth of evidence on new circuit-based TMS targets. This leaves the clinician with a challenging conundrum. When is the evidence strong enough to use a target clinically? When there is no clinical trial, can we learn from cohort studies? How valuable are lesion studies or functional neuroimaging studies? And how do I bring together all of this information to give my patient the best possible treatment? Fortunately, we don’t need to reinvent the wheel - there are several guidelines on how to weigh evidence across medicine. In this session, we will discuss how to apply these guidelines to circuit-targeted brain stimulation.

Take advantage of our Q&A portion of the webinar!

At the end of this presentation, participants will be able to identify and understand the following: 

  1. Describe emerging approaches for targeting brain circuits with TMS
  2. Appraise evidence for emerging circuit-based treatment targets
  3. Identify treatment targets that have strong evidence-based support

Format: On-Demand

Cost: Members: $25 | Non-members $50 | Student Members FREE


Shan Siddiqi, MD

Dr. Shan Siddiqi




Dr. Siddiqi’s research is focused on mapping new TMS targets for neuropsychiatric disorders based on causal mapping of human brain function and dysfunction. Using techniques such as functional connectivity MRI, his lab maps brain circuits to link brain lesions and brain stimulation sites that can modify different psychiatric symptoms. These circuits can then be targeted with treatments such as transcranial magnetic stimulation (TMS) and deep brain stimulation (DBS) to alleviate psychiatric symptoms. His work has been recognized with multiple awards from the Brain & Behavior Research Foundation, the American Neuropsychiatric Association, the American College of Neuropsychopharmacology, Harvard Medical School, and many others.